Skip to content
Pharma Observatory a Scientist.com platform

Clinical trial

A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors

NCT01515306 is registered in ClinicalTrials.gov with Eli Lilly and Company as lead sponsor.

NCT NCT01515306
Email me this page as a PDF

Search trials, sites, companies and investigators, and follow each one to the others. Individual plan, $249/seat/mo. Card required.

Get the NCT01515306 report as a PDF

The PDF carries up to 50 rows of each section, where the page shows the first few, with the sources listed. Enter a work email and confirm it from the message we send, and the report follows by email.

Registry record

As filed in ClinicalTrials.gov.

Title
A Study to Evaluate the Potential of Concomitant Ramucirumab to Affect the Pharmacokinetics of Paclitaxel in Patients With Advanced Malignant Solid Tumors
Lead sponsor
Eli Lilly and Company
Phase
Phase 2
Overall status
Completed
Start date
July 19, 2012
Completion date
February 22, 2021
Enrollment
48 (actual)
Sites
6

Conditions

As the registry lists them; a condition with its own page is linked.

malignant solid tumor